Table 1.
Participant characteristics at baseline
| Participant characteristics | All | Males | Females |
|---|---|---|---|
| Patients, n (right eyes) | 26 (14) | 16 (9) | 10 (5) |
| Age, years | 67.4 (10.6) | 68.8 (9.9) | 62.2 (11.70 |
| Phakic:pseudophakic eyes, n | 9:17 | 6:10 | 3:7 |
| BCVA, EDTRS letters | 69.7 (6.2) | 70.9 (6.3) | 67.8 (5.6) |
| CFT, µm | 416.6 (121.3) | 404.4 (93.5) | 436.1 (157.1) |
| CSVol mm3 | 10.0 (1.6) | 10.0 (1.5) | 10.3 (1.5) |
| Diabetes mellitus type 1, n | 3 | 2 | 1 |
| Insulin treatment, n | 22 | 13 | 9 |
| Baseline HbA1c, % | 8.16 (1.32) | 7.8 (1.36) | 8.64 (1.17) |
| De novo ME, n | 15 | 11 | 4 |
| Diabetic retinopathy history, years | 4.1 (3.4) | 3.8 (3.0) | 4.7 (3.2) |
| Previous laser, n | 13 | 9 | 4 |
| Previous anti-VEGF, n | 7 | 4 | 3 |
Values in table are presented as the mean with the standard deviation (SD) in parenthesis, unless indicated otherwise
BCVA Best-corrected visual acuity measured after refraction using Early Treatment Diabetic Retinopathy Study (ETDRS) charts, CFT central retinal thickness within 1 mm of the fovea, CSVol central subfoveal volume within 6 mm of the fovea, HbA1c glycosylated hemoglobin, ME macular edema, n number of participants (eyes) in that category, VEGF vascular endothelial growth factor